



Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes

Pedro Cardoso¹ · Katie G. Young¹ · Anand T. N. Nair² · Rhian Hopkins¹ · Andrew P. McGovern¹ · Eram Haider² · Piyumanga Karunaratne² · Louise Donnelly² · Bilal A. Mateen³ · Naveed Sattar⁴ · Rury R. Holman^{5,6} · Jack Bowden¹ · Andrew T. Hattersley¹ · Ewan R. Pearson² · Angus G. Jones¹ · Beverley M. Shields¹ · Trevelyan J. McKinley¹ · John M. Dennis¹ on behalf of the MASTERMIND consortium

Received: 17 October 2023 / Accepted: 4 January 2024 / Published online: 22 February 2024
© The Author(s) 2024

Abstract

Aims/hypothesis A precision medicine approach in type 2 diabetes could enhance targeting specific glucose-lowering therapies to individual patients most likely to benefit. We aimed to use the recently developed Bayesian causal forest (BCF) method to develop and validate an individualised treatment selection algorithm for two major type 2 diabetes drug classes, sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA).

Methods We designed a predictive algorithm using BCF to estimate individual-level conditional average treatment effects for 12-month glycaemic outcome (HbA_{1c}) between SGLT2i and GLP1-RA, based on routine clinical features of 46,394 people with type 2 diabetes in primary care in England (Clinical Practice Research Datalink; 27,319 for model development, 19,075 for hold-out validation), with additional external validation in 2252 people with type 2 diabetes from Scotland (SCI-Diabetes [Tayside & Fife]). Differences in glycaemic outcome with GLP1-RA by sex seen in clinical data were replicated in clinical trial data (HARMONY programme: liraglutide [$n=389$] and albiglutide [$n=1682$]). As secondary outcomes, we evaluated the impacts of targeting therapy based on glycaemic response on weight change, tolerability and longer-term risk of new-onset microvascular complications, macrovascular complications and adverse kidney events.

Results Model development identified marked heterogeneity in glycaemic response, with 4787 (17.5%) of the development cohort having a predicted HbA_{1c} benefit >3 mmol/mol (>0.3%) with SGLT2i over GLP1-RA and 5551 (20.3%) having a predicted HbA_{1c} benefit >3 mmol/mol with GLP1-RA over SGLT2i. Calibration was good in hold-back validation, and external validation in an independent Scottish dataset identified clear differences in glycaemic outcomes between those predicted to benefit from each therapy. Sex, with women markedly more responsive to GLP1-RA, was identified as a major treatment effect modifier in both the UK observational datasets and in clinical trial data: HARMONY-7 liraglutide (GLP1-RA): 4.4 mmol/mol (95% credible interval [95% CrI] 2.2, 6.3) (0.4% [95% CrI 0.2, 0.6]) greater response in women than men. Targeting the two therapies based on predicted glycaemic response was also associated with improvements in short-term tolerability and long-term risk of new-onset microvascular complications.

Conclusions/interpretation Precision medicine approaches can facilitate effective individualised treatment choice between SGLT2i and GLP1-RA therapies, and the use of routinely collected clinical features for treatment selection could support low-cost deployment in many countries.

Keywords Bayesian non-parametric modelling · GLP1-receptor agonists · Heterogeneous treatment effects · Precision medicine · SGLT2-inhibitors · Type 2 diabetes

Abbreviations

95% CrI 95% Credible interval
ALT Alanine aminotransferase

ATE Average treatment effect
BCF Bayesian causal forest
CATE Conditional average treatment effect
CKD Chronic kidney disease
CPRD UK Clinical Practice Research Datalink
DPP4i DPP4 inhibitors
GLP-1 Glucagon-like peptide-1

Trevelyan J. McKinley and John M. Dennis are joint senior authors.

Extended author information available on the last page of the article

Research in context

What is already known about this subject?

- Current type 2 diabetes treatment guidelines recommend SGLT2-inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1-RA) for specific subgroups based on cardiorenal disease profile. However, this approach lacks specific guidance for the broader type 2 diabetes population
- Recent studies demonstrate a clear potential for targeting specific glucose-lowering medications to individuals with type 2 diabetes based on their clinical characteristics, but have not evaluated the relative efficacy of SGLT2i compared with GLP1-RA

What is the key question?

- Can a model predicting differential glycaemic response between SGLT2i and GLP1-RA using routine clinical features support individualised decisions on treatment choice, and what is the potential impact of targeting SGLT2i and GLP1-RA treatment based on glycaemic response on weight change, tolerability and risk of microvascular and macrovascular complications?

What are the new findings?

- Clinical characteristics alter the relative glycaemic efficacy of SGLT2i compared with GLP1-RA. In our study, 17.5% of individuals had a predicted HbA_{1c} benefit >3 mmol/mol (>0.3%) with SGLT2i over GLP1-RA and 20.3% had a predicted HbA_{1c} benefit >3 mmol/mol with GLP1-RA over SGLT2i
- Women, compared with men, have a greater glycaemic response with GLP1-RA in both observational and clinical trial data
- A precision treatment approach of targeting SGLT2i and GLP1-RA based on differential glycaemic response is associated with higher short-term tolerability and a lower risk of developing new-onset microvascular complications

How might this impact on clinical practice in the foreseeable future?

- Our study provides robust predictions of differences in the glycaemic efficacy of SGLT2i and GLP1-RA based on the routine clinical characteristics of individual patients, providing a low-cost approach to precision treatment for people with type 2 diabetes

GLP1-RA	Glucagon-like peptide-1 receptor agonists
MACE	Major adverse cardiovascular events
SGLT2i	Sodium–glucose cotransporter 2 inhibitors

Introduction

A precision medicine approach in type 2 diabetes would aim to target specific glucose-lowering therapies to individual patients most likely to benefit [1]. Current stratification in type 2 diabetes treatment guidelines involves preferential prescribing of two major drug classes, sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA), to subgroups of people with or at high risk of cardiorenal disease [2]. Evidence informing these recommendations comes from average treatment effect (ATE) estimates derived from placebo-controlled cardiovascular and renal outcome trials, which have

predominantly recruited participants with advanced atherosclerotic cardiovascular risk or established cardiovascular disease [3, 4]. Consequently, there is limited evidence on the benefits of SGLT2i and GLP1-RA for individuals in the broader type 2 diabetes population and, given the lack of head-to-head trials, of the relative efficacy of the two drug classes for individual patients.

Recent studies have demonstrated a clear potential for a precision medicine approach based on glycaemic response, with the TRIMASTER crossover trial establishing a greater efficacy of SGLT2i compared with DPP4 inhibitors (DPP4i) in those with better renal function, and a greater efficacy of thiazolidinedione therapy compared with DPP4i in those with obesity (BMI > 30 kg/m²) compared to those without obesity [5]. Given these findings, a trial-data-validated prediction model to support individualised treatment selection has recently been developed for SGLT2i vs DPP4i therapy [6]. For GLP1-RA, although recent studies have identified robust heterogeneity in treatment response based on

pharmacogenetic markers and markers of insulin secretion [7, 8], the influence of these markers on relative differences in clinical outcomes compared with other drug classes, and therefore their utility for targeting treatment, has not previously been assessed.

Given the lack of evidence to support targeted treatment of SGLT2i compared with GLP1-RA therapies, we aimed to develop and validate a prediction model to provide individual patient-level estimates of differences in 12-month glycaemic (HbA_{1c}) outcomes for the two drug classes based on routinely collected clinical features. We also evaluated the downstream impacts of targeting therapy based on glycaemic response on secondary outcomes of weight change, tolerability and longer-term risk of new-onset microvascular complications, macrovascular complications and adverse kidney events.

Methods

Study population Individuals with type 2 diabetes initiating SGLT2i and GLP1-RA therapies between 1 January 2013 and 31 October 2020 were identified in the UK population-representative Clinical Practice Research Datalink (CPRD) Aurum dataset [9], following our previously published cohort profile [10] (see <https://github.com/Exeter-Diabetes/CPRD-Codelists> for all codelists). We excluded individuals prescribed either therapy as first-line treatment (not recommended in UK guidelines) [11], co-treated with insulin, and with a diagnosis of end-stage renal disease (ESRD) (electronic supplementary material [ESM] Fig. 1). Owing to low numbers, we also excluded individuals initiating the GLP1-RA semaglutide ($n=784$ study-eligible individuals with outcome HbA_{1c} recorded) [12]. The final CPRD cohort was randomly split 60:40 into development and hold-back validation sets, maintaining the proportion of individuals receiving SGLT2i and GLP1-RA in each set. For model development, individuals were excluded from the development and validation sets if they initiated multiple glucose-lowering treatments on the same day; their therapies were initiated less than 61 days since the start of a previous therapy; their baseline HbA_{1c} was <53 mmol/mol (7%); they had a missing baseline HbA_{1c}; or they had a missing outcome HbA_{1c} (Table 1, ESM Fig. 1).

Additional cohorts The same eligibility criteria were applied to define an independent cohort in Scotland for model validation (SCI-Diabetes [Tayside & Fife], containing longitudinal observational data including biochemical investigations and prescriptions). To assess reproducibility of differences in HbA_{1c} response by sex with GLP1-RA therapy, we accessed individual-level data on participants initiating the GLP1-RAs albiglutide and liraglutide in the HARMONY

clinical trial programme (sponsored by GlaxoSmithKline [GSK]), an international randomised placebo-controlled trial designed to evaluate the cardiovascular benefit of albiglutide with type 2 diabetes [13], and the Predicting Response to Incretin Based Agents (PRIBA) prospective cohort study (UK 2011–2013) [14], designed to test whether individuals with low insulin secretion have lesser glycaemic response to incretin-based treatments.

Outcomes The primary outcome was achieved HbA_{1c} at 12 months post drug initiation on unchanged glucose-lowering therapy. Given the variability in the timing of follow-up testing in UK primary care, this outcome was defined as the closest eligible HbA_{1c} value to 12 months (within 3–15 months) after initiation. To allow for potential differential effects of follow-up duration on HbA_{1c}, we included an additional covariate to capture the month the outcome HbA_{1c} was recorded.

Secondary outcomes comprised short-term 12 month weight change after initiation (closest recorded weight to 12 months, within 3–15 months), and, as a proxy for drug tolerability, treatment discontinuation within 6 months of drug initiation (as such short-term discontinuation is unlikely to be related to a lack of glycaemic response), and longer-term outcomes up to 5 years after initiation: new-onset major adverse cardiovascular events (MACE: composite of myocardial infarction, stroke and cardiovascular death); new-onset heart failure; new-onset adverse kidney outcome (a drop of $\geq 40\%$ in eGFR from baseline or reaching chronic kidney disease [CKD] stage 5 [7]); and new-onset microvascular complications (ESM Fig. 2). We focused on only new-onset cardiorenal events (excluding individuals with pre-existing conditions of interest), as those with pre-existing disease have a clear indication for SGLT2i and GLP1-RA in current guidelines irrespective of differences in glycaemic outcome.

Predictors Candidate predictors were selected to represent readily available (available in $>75\%$ of individuals) routine clinical features and comprised current age, duration of diabetes, year of therapy start, sex (self-reported), ethnicity (self-reported, categorised into major UK groups: White, South Asian, Black, Mixed, other), social deprivation (index of multiple deprivation quintile), smoking status, the number of current, and ever, prescribed glucose-lowering drug classes, baseline HbA_{1c} (closest to treatment start date; range in previous 6 months to +7 days), clinical parameters: BMI, eGFR (CKD-EPI formula [15]), HDL-cholesterol, alanine aminotransferase (ALT), albumin, bilirubin, total cholesterol and mean arterial blood pressure (all defined as closest values to treatment start in the previous two years), microvascular complications: nephropathy, neuropathy, retinopathy, and major comorbidities: angina, atherosclerotic cardiovascular

Table 1 Baseline clinical characteristics of patients initiating GLP1-RA and SGLT2i from the CPRD

Baseline characteristic	GLP1-RA (<i>n</i> =28,081)		SGLT2i (<i>n</i> =84,193)		SMD
		Missing (%)		Missing (%)	
Current age, years	57.7 [11.2]		58.4 [10.8]		0.064
Duration of diabetes, years	9.4 [6.4]		9.4 [6.6]		0.012
Year of drug start	2017 [2]		2017 [2]		0.390
Sex					0.155
Male	14,960 (53.3)		51,288 (60.9)		
Female	13,121 (46.7)		32,905 (39.1)		
Ethnicity					0.255
White	24,063 (85.7)		64,111 (76.1)		
South Asian	2144 (7.6)		12,234 (14.5)		
Black	987 (3.5)		3861 (4.6)		
Other	262 (0.9)		1316 (1.6)		
Mixed	246 (0.9)		885 (1.1)		
Missing	379 (1.3)		1786 (2.1)		
SGLT2i type					
Canagliflozin			14,965 (17.8)		
Dapagliflozin			36,250 (43.1)		
Empagliflozin			32,860 (39.0)		
Ertugliflozin			137 (0.2)		
GLP1-RA type					
Dulaglutide	10,337 (36.8)				
Exenatide (short-acting)	1367 (4.9)				
Exenatide (long-acting)	2377 (8.5)				
Liraglutide	11,260 (40.1)				
Lixisenatide	2751 (9.8)				
Index of multiple deprivation		18 (0.1)		47 (0.1)	0.033
1 (Least deprived)	4568 (16.3)		14,143 (16.8)		
2	4925 (17.5)		14,836 (17.6)		
3	5393 (19.2)		16,194 (19.2)		
4	6099 (21.7)		18,841 (22.4)		
5 (Most deprived)	7078 (25.2)		20,132 (23.9)		
Smoking status					0.048
Active	4689 (16.7)		14,265 (16.9)		
Ex-smoker	15,543 (55.4)		45,283 (53.8)		
Non-smoker	6605 (23.5)		21,311 (25.3)		
Missing	1244 (4.4)		3334 (4.0)		
Number of glucose-lowering drug classes ever prescribed					0.420
2	2886 (10.3)		18,724 (22.2)		
3	6772 (24.1)		25,570 (30.4)		
4	10,536 (37.5)		25,217 (30.0)		
≥5	7887 (28.1)		14,682 (17.4)		
Number of other current glucose-lowering drugs					0.137
0	1161 (4.1)		5155 (6.1)		
1	9948 (35.4)		34,032 (40.4)		
2	12,422 (44.2)		35,540 (42.2)		
3	3862 (13.8)		9187 (10.9)		
≥4	233 (0.8)		279 (0.3)		
Background therapy					
Metformin	24,075 (85.7)		73,392 (87.2)		0.042

Table 1 (continued)

Baseline characteristic	GLP1-RA (<i>n</i> =28,081)		SGLT2i (<i>n</i> =84,193)		SMD
		Missing (%)		Missing (%)	
Sulfonylurea	13,312 (47.4)		30,165 (35.8)		0.237
DPP4i	4595 (16.4)		23,256 (27.6)		0.274
SGLT2i	4019 (14.3)				–
Thiazolidinedione	1312 (4.7)		2374 (2.8)		0.098
GLP1-RA			4603 (5.5)		–
Biomarkers					
HbA _{1c} , mmol/mol ^a	78.6 [17.1]	5795 (20.6)	76.9 [16.9]	10,252 (12.2)	0.101
HbA _{1c} , % ^a	9.3 [3.7]	5795 (20.6)	9.2 [3.7]	10,252 (12.2)	0.101
BMI, kg/m ²	37.3 [7.2]	771 (2.7)	33.7 [6.9]	3234 (3.8)	0.522
eGFR, ml/min per 1.73 m ²	92.0 [19.7]	68 (0.2)	94.7 [15.5]	217 (0.3)	0.152
HDL-cholesterol, mmol/l	1.1 [0.3]	1333 (4.7)	1.1 [0.3]	3019 (3.6)	0.083
ALT, IU/l	35.1 [20.6]	1801 (6.4)	34.5 [20.2]	4841 (5.7)	0.027
Albumin, g/l	41.6 [3.9]	1347 (4.8)	42.0 [3.9]	3667 (4.4)	0.109
Bilirubin, μmol/l	9.1 [4.7]	1187 (4.2)	9.5 [5.0]	3385 (4.0)	0.084
Total cholesterol, mmol/l	4.4 [1.1]	167 (0.6)	4.3 [1.1]	398 (0.5)	0.039
Mean arterial BP, mmHg	96.1 [9.0]	82 (0.3)	96.2 [9.0]	270 (0.3)	0.016
Microvascular complications					
Nephropathy	730 (2.6)		1623 (1.9)		0.045
Neuropathy	7942 (28.3)		20,161 (23.9)		0.099
Retinopathy	10,540 (37.5)		31,664 (37.6)		0.002
Cardiovascular conditions					
Angina	3224 (11.5)		8251 (9.8)		0.055
Atherosclerotic CVD ^a	6285 (22.4)		16,530 (19.6)		0.068
Atrial fibrillation	1737 (6.2)		4129 (4.9)		0.056
Cardiac revascularisation	1863 (6.6)		5632 (6.7)		0.002
Heart failure	1662 (5.9)		3654 (4.3)		0.072
Hypertension	16,833 (59.9)		46,550 (55.3)		0.094
Ischaemic heart disease	4181 (14.9)		11,309 (13.4)		0.042
Myocardial infarction	1943 (6.9)		5655 (6.7)		0.008
Peripheral arterial disease	1703 (6.1)		3836 (4.6)		0.067
Stroke	1270 (4.5)		3422 (4.1)		0.023
Transient ischaemic attack	766 (2.7)		2126 (2.5)		0.013
Other conditions					
CKD	2684 (9.6)		2962 (3.5)		0.246
Chronic liver disease	3754 (13.4)		10,241 (12.2)		0.036
QRISK2 10-year score	23.5 [13.5]	1573 (5.6)	23.5 [13.2]	6215 (7.4)	0.006
HbA_{1c} outcome					
HbA _{1c} , mmol/mol	66.3 [18.3]	15,397 (54.8)	64.2 [15.0]	40,025 (47.5)	0.126
HbA _{1c} , %	8.2 [3.8]	15,397 (54.8)	8.0 [3.5]	40,025 (47.5)	0.126
Month of HbA _{1c} measure	8.9 [3.5]	15,397 (54.8)	9.2 [3.5]	40,025 (47.5)	0.071

Data are mean [SD] and number (%)

SMD: Standardised mean difference (≥ 0.1 is a common metric for a meaningful imbalance between treatment groups). Atherosclerotic cardiovascular disease: composite of myocardial infarction, stroke, ischaemic heart disease, peripheral arterial disease and revascularisation

^aClosest values to treatment start in the previous 6 months

disease, atrial fibrillation, cardiac revascularisation, heart failure, hypertension, ischaemic heart disease, myocardial infarction, peripheral arterial disease, stroke, transient ischaemic attack, CKD and chronic liver disease.

Treatment selection model development We used the recently proposed Bayesian causal forest (BCF) structure, a framework specifically designed to estimate heterogeneous treatment effects (henceforth: conditional average treatment effects [CATEs]) [16, 17] (ESM Methods: Model overview). The CATE for an individual is conditional on their clinical characteristics, and represents the predicted differential effects of the two drug classes on HbA_{1c} outcome. The BCF framework also minimises confounding from indication bias and allows for flexibility in defining model structure and outputs, and is an extension of Bayesian additive regression tree (BART) counterfactual models [18]. The model development process consisted of a first step of propensity score estimation to minimise confounding due to prescribing by indication [19], (ESM Methods: Propensity score estimation), and a second step of model development, using the R packages *bcf* (version 2.0.1) [17] and *sparseBCF* (version 1.0) [19] packages. Variable selection, based on each variable's splitting probabilities, was deployed to develop a parsimonious final model whilst maintaining predictive accuracy (ESM Methods: Variable selection). The propensity score was not included in the final predictor set as it did not meet our threshold for variable selection (ESM Methods: Final model fit); however, as a sensitivity analysis, we refitted the final model, including the propensity score in the predictor set and compared predictions across the two models. Currently, the standard BCF software cannot account for missing data [20], so we used a complete case analysis, informed by our previous study showing a limited impact of missing data on predicting CATE in a similar primary care dataset [21]. To evaluate the degree of model-predicted treatment effect heterogeneity, differential HbA_{1c} response—the difference in achieved HbA_{1c} between drug classes—was extracted from the final model for all individuals.

Variable importance was estimated based on best linear projection (ESM Methods: Variable importance). To assess how CATE estimates varied across major routine clinical features, we also summarised the marginal distributions of key predictor variables (sex, baseline HbA_{1c}, eGFR, current age and BMI) across subgroups defined by the degree of predicted glycaemic differences (SGLT2i benefit of 0–3, 3–5 or >5 mmol/mol [0–0.3, 0.3–0.5 or >0.5%]; GLP1-RA benefit of 0–3, 3–5 or >5 mmol/mol).

Model validation Evaluating the accuracy of predicted CATE is a significant challenge since, in practice, true CATE estimates are unobserved as a single individual receives only one therapy, meaning the counterfactual outcome they would have had on the alternative therapy is unobserved [22]. As

such, to validate predicted CATE estimates, we first split validation sets into subgroups based on predicted CATE estimates and then compared the average CATE estimate within each subgroup to estimates derived from a set of alternative models fitted to each of the subgroups in turn. These latter models target the average treatment effect (ATE) within a population of individuals (rather than the conditional average treatment effect [CATE]), with desirable properties justified in the literature [23]. This validation framework further develops the concordant–discordant approach previously proposed in Dennis et al [6]. If the average CATE estimates in each subgroup (from the BCF model) align with the ATE estimates from the alternative models, this provides evidence that ATEs are consistent across different inference methods within each subgroup. Restricting the ATE estimates for each subgroup allows for simpler comparison ATE models to be used, since the distribution of covariates in each subgroup is expected to be more consistent within each subgroup than for the complete data. For validation, subgroups were defined by decile of predicted CATE in CPRD and, owing to the smaller cohort size, by quintile in Tayside & Fife.

To estimate the ATEs within subgroups, we used regression adjustment as the primary approach, estimating the ATE as the average difference in HbA_{1c} outcome between individuals receiving each therapy class within each subgroup Bayesian linear regression, adjusting for the full covariate set used in the HbA_{1c} treatment selection model (full covariate set; Table 2), with all continuous predictors included as 3-knot restricted cubic splines [6]. As a sensitivity analysis, we estimated CATE using propensity score matching with and without regression adjustment (ESM Methods).

As our overall dataset predominantly included individuals of white ethnicity, we assessed the accuracy of predicted HbA_{1c} treatment effects in a subgroup of individuals of South Asian, Black, Other and Mixed ethnicity. We also evaluated accuracy of predicted HbA_{1c} treatment effects in those with and without cardiovascular disease. We also evaluated the reproducibility of observed differences in HbA_{1c} response by sex in participants receiving GLP1-RA in the HARMONY clinical trial, the PRIBA prospective study, and Tayside & Fife.

Secondary outcomes Specific cohorts were defined to evaluate each secondary outcome to mitigate selection bias and maximise the number of individuals available for analysis (ESM Fig. 2; ESM Methods: Secondary outcomes). All cohorts required complete predictor data for the HbA_{1c}-based treatment selection model. To evaluate treatment effect heterogeneities, subgroups were defined by the degree of predicted glycaemic differences (SGLT2i benefit of 0–3, 3–5 or >5 mmol/mol [0–0.3, 0.3–0.5 or >0.5%]; GLP1-RA benefit of 0–3, 3–5 or >5 mmol/mol). As for validation of differences in HbA_{1c} outcomes, we evaluated subgroup-level ATEs using regression adjustment as the primary approach, with

Table 2 Baseline clinical features included in the treatment selection algorithm after variable selection

Features predictive of HbA _{1c} outcome with SGLT2i	Features predictive of differential HbA _{1c} outcome with GLP1-RA compared with SGLT2i
Current age	Current age
Duration of diabetes	Sex
Number of glucose-lowering drug classes ever prescribed	Number of other current glucose-lowering drugs
Number of other current glucose-lowering drugs	Baseline HbA _{1c}
Baseline HbA _{1c}	BMI
eGFR	eGFR
ALT	Heart failure
Peripheral arterial disease	Ischaemic heart disease
	Neuropathy
	Peripheral arterial disease
	Retinopathy

The BCF treatment selection model is structured into two parts: a part that identifies features predictive of HbA_{1c} outcome with SGLT2i, and a part that identifies differential HbA_{1c} outcome with GLP1-RA compared with SGLT2i. HbA_{1c} outcome with SGLT2i is estimated using the set of features on the left of the table, HbA_{1c} outcome with GLP1-RA is estimated using both sets of features in the table

propensity score matching with and without regression adjustment deployed as sensitivity analysis. For evaluation of new-onset cardiovascular and renal outcomes, the propensity score model was refitted incorporating baseline cardiovascular risk as an additional predictor (QRISK2 predicted probability of new-onset myocardial infarction or stroke [24]). Absolute HbA_{1c} response was evaluated by drug class as adjusted (full covariate set) HbA_{1c} change from baseline using Bayesian linear regression. To evaluate differences by drug class in 12 month weight change, we included all individuals with a recorded baseline weight (closest value to 2 years prior to treatment initiation) and a valid outcome weight. Treatment effects were estimated using an adjusted (full covariate set) Bayesian linear regression model with an interaction between the received treatment and the predicted HbA_{1c} treatment benefit subgroup, with adjustment for baseline weight. Similarly, differences in treatment discontinuation were estimated using adjusted (full covariate set) Bayesian logistic regression with a treatment-by-HbA_{1c} benefit subgroup interaction.

For longer-term outcomes, we included only individuals without the outcome of interest at therapy initiation, thus evaluating only incident events. Individuals were followed for up to 5 years using an intention-to-treat approach from the date of therapy initiation until the earliest of: the outcome of interest, the date of general practitioner (GP) practice deregistration or death, or the end of the study period. For each outcome, adjusted (full covariate set) Bayesian Cox proportional hazards models with treatment-by-HbA_{1c} benefit subgroup interactions were fitted with additional adjustment for QRISK2 predicted probability of new-onset myocardial infarction or stroke.

All analyses were conducted using R (version 4.1.2; R Foundation for Statistical Computing, Austria). We followed TRIPOD prediction model reporting guidance (ESM Materials) [25].

Results

We included 84,193 people with type 2 diabetes initiating SGLT2i and 28,081 initiating GLP1-RA (ESM Fig. 1). The mean age of individuals was 58.2 (SD=10.9) years, 66,248 (59%) were men, and 88,174 (79%) were of white ethnicity. Baseline clinical characteristics by initiated drug class are reported in Table 1.

Model development For the development of the 12 month HbA_{1c} response treatment selection model, individuals with a measured HbA_{1c} outcome were randomly split 60:40 into development ($n=31,346$) and validation ($n=20,865$) cohorts (ESM Fig. 1; Baseline characteristics by cohort: ESM Table 1). Mean unadjusted 12 month HbA_{1c} response (change from baseline in HbA_{1c}) was -12.0 (SD 15.3) mmol/mol (-1.1% [SD 1.4%]) for SGLT2i and -11.7 (SD 17.6) mmol/mol (-1.1% [SD 1.6%]) for GLP1-RA.

After variable selection [26] (ESM Fig. 3), we identified multiple clinical factors predictive of HbA_{1c} response with SGLT2i (the reference drug class in the model), and multiple factors predictive of differential HbA_{1c} response with GLP1-RA compared with SGLT2i therapy (Table 2). The final BCF model was fitted to 27,319 (87.2% of the starting development cohort) individuals with complete data for all selected clinical factors. In sensitivity analysis, the model predictions for final BCF model were similar to the BCF model with the full covariate set (ESM Fig. 4). Overall model fit and performance statistics for predicting achieved HbA_{1c} outcome in internal validation for both the development and hold-out cohorts are reported in ESM Table 2. The propensity score did not meet the criteria for variable selection, and model predictions were similar when adding a propensity score as an additional covariate as a sensitivity analysis (ESM Fig. 5). The variable




Fig. 1 Predicted CATE effects and model calibration. **(a)** Distribution of CATE estimates for SGLT2i vs GLP1-RA in the CPRD development cohort; negative values reflect a predicted HbA_{1c} treatment benefit on SGLT2i and positive values reflect a predicted treatment benefit on GLP1-RA. **(b)** Calibration between ATE and predicted CATE

selection and performance of the propensity score model are reported in ESM (ESM Fig. 6–7).

In the development cohort, the mean CATE across all individuals was a 0.1 mmol/mol (95% credible interval [CrI] −0.3, 0.5) (0.01% [95% CrI −0.03, 0.05]) benefit with GLP1-RA over SGLT2i, suggesting similar average efficacy of both therapies. However, between individuals, there was marked heterogeneity in the predicted CATE estimates (Fig. 1a), with the model predicting a mean HbA_{1c} benefit on SGLT2i therapy for 13,110 (48%) individuals and on GLP1-RA for 14,209 (52%) individuals. In the development cohort, 4787 (17.5%) had a predicted HbA_{1c} benefit >3 mmol/mol (0.3%) (3 mmol/mol is used widely as minimally important difference in clinical trials) with SGLT2i over GLP1-RA, and 5551 (20.3%) had a predicted HbA_{1c} benefit >3 mmol/mol with GLP1-RA over SGLT2i.

Model calibration Calibration by decile of model-predicted CATE estimates was good in the development cohort ($n=27,319$; Fig. 1b), the hold-back CPRD validation cohort ($n=19,075$, Fig. 1c), and in propensity-matched cohorts (ESM Fig. 8).

In the external Scottish cohort (Tayside & Fife; $n=2252$ [1837 initiating SGLT2i, 415 initiating GLP1-RA]; baseline characteristics: ESM Table 1), a similar distribution of predicted CATE to CPRD was observed (Fig. 2a), and there was a clear difference between upper (favouring GLP1-RA) and lower (favouring SGLT2i) quintiles, but modest calibration in middle quintiles (Fig. 2b). Among 81 (3.6%) individuals with a model-predicted HbA_{1c} benefit >5 mmol/mol (>0.5%) for SGLT2i over GLP1-RA, there was a 7.4 mmol/mol (95%


estimates, by decile of predicted CATE in the development cohort. **(c)** Calibration of CATE estimates in the validation cohort. ATE estimates are adjusted for all the variables used in the treatment selection model (see [Methods](#))

CrI 0.1, 14.8) (0.7% [95% CrI 0, 1.4]) benefit for SGLT2i (Fig. 2c). In contrast, among 150 (6.7%) individuals with a model-predicted HbA_{1c} benefit >5 mmol/mol for GLP1-RA over SGLT2i, there was a 5.6 mmol/mol (95% CrI −0.9, 12.1) (0.5% [95% CrI −0.1, 1.1]) benefit for GLP1-RA.

Model interpretability Stratifying the combined development and validation cohorts ($n=46,394$ with complete predictor data) into subgroups defined by predicted CATE, there were clear differences in clinical characteristics, with those having a greater predicted HbA_{1c} benefit with GLP1-RA over SGLT2i being predominantly female and older, with lower baseline HbA_{1c}, eGFR and BMI (Fig. 3a–e, ESM Table 1). SGLT2i were predicted to have a greater HbA_{1c} benefit over GLP1-RA for 32% of those with baseline HbA_{1c} levels <64 mmol/mol (8%), compared to 67% of those with baseline HbA_{1c} ≥ 86 mmol/mol ($\geq 10\%$). An evaluation of relative variable importance identified the number of other current glucose-lowering drugs (a higher number of concurrent therapies favouring SGLT2i as the optimal treatment), sex, current age, and to a lesser extent BMI and HbA_{1c} as the most influential predictors (relative importance $\geq 3\%$). In contrast, microvascular complications and cardiovascular comorbidities had very modest effects on differential response (ESM Fig. 9).

Replication of sex differences in glycaemic response in clinical trials Whilst previous analyses of clinical trials and observational data for SGLT2i have shown a modestly greater HbA_{1c} response in men compared with women, which we additionally reproduced in Tayside & Fife (Fig. 4a,b), sex differences in

Fig. 2 External validation in Tayside & Fife, Scotland ($n=2252$). **(a)** Distribution of CATE estimates for SGLT2i vs GLP1-RA; negative values reflect a predicted glucose-lowering treatment benefit on SGLT2i and positive values reflect a predicted treatment benefit on GLP1-RA. **(b)** Calibration between adjusted ATE and predicted CATE estimates, by quintile of predicted CATE. **(c)** ATE estimates within subgroups defined by clinically meaningful CATE thresholds (SGLT2i benefit >5, 3–5 and 0–3 mmol/mol, GLP1-RA benefit >5, 3–5 and 0–3 mmol/mol). Bars represent 95% CrI



GLP1-RA response have not been clearly established. Here, we focused on individual-level randomised clinical trial data of GLP1-RA from the HARMONY programme (liraglutide [$n=389$] and albiglutide [$n=1682$]) [18], the PRIBA prospective cohort study (non-insulin treated participants only: liraglutide [$n=350$], exenatide [$n=197$], lixisenatide [$n=3$]) [14], and Tayside & Fife ($n=415$). Baseline characteristics for the cohorts are reported in ESM Table 1. Across all studies, there was consistent evidence of a greater baseline HbA_{1c} adjusted glycaemic response in women vs men; this was most marked for liraglutide in the HARMONY 7 trial [7] where a 4.4 mmol/mol (95% CrI 2.2, 6.3) (0.4% [95% CrI 0.2, 0.6]) greater response in women vs men was observed.

Effect of targeting therapy based on differential HbA_{1c} outcome on other short- and long-term outcomes Specific subpopulations were defined for each short-term outcome to maximise the number of eligible individuals for each analysis and based on the availability of observed outcome data (12 month HbA_{1c} change from baseline [to evaluate absolute response] $n=87,835$;

12 month weight change $n=41,728$; treatment discontinuation within 6 months [a proxy for tolerability] $n=77,741$) (ESM Fig. 2). Longer-term outcomes were evaluated up to 5 years from drug initiation, excluding individuals with a history of cardiovascular disease or CKD for MACE, heart failure, and adverse kidney (composite of $\geq 40\%$ decline in eGFR or kidney failure [14]) outcomes ($n=52,052$) and individuals with a history of retinopathy, neuropathy and nephropathy for microvascular outcome ($n=34,524$). (ESM Fig. 2).

For HbA_{1c} change from baseline, of the 6856 individuals (7.8%) with a predicted HbA_{1c} benefit on SGLT2i of >5 mmol/mol (>0.5%), those who received SGLT2i had a 23.3 mmol/mol (95% CrI 22.6, 24.0) (2.1% [95% CrI 2.1, 2.2]) mean reduction in HbA_{1c} and those who received GLP1-RA had an 18.4 mmol/mol (95% CrI 17.6, 19.3) (1.7% [95% CrI 1.6, 1.8]) mean reduction in HbA_{1c} (Fig. 5a). In contrast, of the 7293 individuals (8.3%) with a predicted HbA_{1c} benefit on GLP1-RA of >5 mmol/mol, those receiving GLP1-RA had a 15.7 mmol/mol (95% CrI 14.8, 16.6) (1.4% [95% CrI 1.4, 1.5]) mean reduction in HbA_{1c}, and those receiving SGLT2i




Fig. 3 Distributions of major clinical characteristics predicting differential HbA_{1c} outcome with SGLT2i and GLP1-RA. Distributions of key differential clinical characteristics in the combined development and validation cohorts (*n*=46,394 with complete predictor data) for subgroups defined by predicted HbA_{1c} outcome differences: SGLT2i benefit >5 mmol/mol, 3–5 mmol/mol and 0–3 mmol/mol, GLP1-RA

benefit >5 mmol/mol, 3–5 mmol/mol and 0–3 mmol/mol. The box and whisker plots include median, first and third quartile, with outliers laying further than 1.5 times the interquartile range. **(a)** Percentage of male individuals in each of the subgroups. **(b)** Baseline HbA_{1c}. **(c)** eGFR. **(d)** Current age. **(e)** BMI




Fig. 4 Differences in HbA_{1c} outcome by sex, in randomised clinical trial and observational datasets. All estimates are adjusted for baseline HbA_{1c}. Estimates lower than zero represent a greater HbA_{1c}

reduction in male compared with female participants. Bars represent 95% CrI. **(a)** SGLT2i: point estimates for the trials meta-analysis and CPRD are reproduced from Dennis et al (2022) [6]. **(b)** GLP1-RA

had a 9.0 mmol/mol (95% CrI 8.2, 9.7) (0.8% [95% CrI 0.8, 0.9]) mean reduction in HbA_{1c}. Consistent differences were observed in individuals of South Asian, Black, Other and Mixed ethnicity (ESM Fig. 10), and those with and without a history of cardiovascular disease (ESM Fig. 11).

Observed weight change was consistently greater for individuals treated with SGLT2i compared with GLP1-RA across all subgroups (Fig. 5b). Short-term discontinuation

was lower in those treated with the drugs predicted to have the greatest glycaemic benefit, mainly reflecting differences in SGLT2 discontinuation across predicted levels of differential glycaemic response (Fig. 5c). Relative risk of new-onset microvascular complications also varied by subgroup, with a lower risk with SGLT2i vs GLP1-RA only in subgroups predicted to have a glycaemic benefit with SGLT2i (Fig. 5d). HRs for the risk of new-onset MACE were similar overall




Fig. 5 Differences in short-term and long-term clinical outcomes with SGLT2i and GLP1-RA for subgroups defined by predicted HbA_{1c} response differences. **(a)** Twelve month HbA_{1c} change from baseline. **(b)** Twelve month weight change. **(c)** Six month risk of discontinuation. **(d)** HR for 5 year risk of new-onset microvascular complications (retinopathy, nephropathy or neuropathy). **(e)** HR for 5 year relative risk of MACE. **(f)** HR for 5 year risk of heart failure. HRs represent the relative risk for those treated with GLP1-RA in comparison with SGLT2i therapy, with a value under 1 favouring SGLT2i therapy. Data underlying the figure are reported in ESM Table 3. Bars represent 95% CI

(HR 1.02 [95% CrI 0.89, 1.18]) and by subgroup (Fig. 5e). HRs for the risks of both new-onset heart failure and adverse kidney outcomes were lower with SGLT2i (heart failure HR 0.71 [95% CrI 0.59, 0.85]; CKD HR 0.41 [95% CrI 0.30, 0.56]) with no clear evidence of a difference by subgroup (Fig. 5f, ESM Fig. 12). Results for all outcomes were consistent in propensity-matched cohorts (ESM Fig. 13–14).

Comparison of model predictions with our previously published treatment selection model for SGLT2i and DPP4i therapies Predictions for HbA_{1c} response with SGLT2i from the SGLT2i v GLP1-RA treatment selection model were highly concordant ($R^2 > 0.92$) with those from our recently published SGLT2i vs DPP4i treatment selection model [6] (ESM Fig. 15). Estimating differential HbA_{1c} responses using both models in our study population with complete data ($n=82,933$) suggested SGLT2i is the predicted optimal therapy for HbA_{1c} in 48.2% ($n=39,975$) of individuals, GLP1-RA the predicted optimal therapy in 51.3% ($n=42,519$), and DPP4i the optimal therapy for only 0.5% ($n=439$).

Prototype treatment selection model A prototype treatment selection model web calculator providing individualised predictions of differences in HbA_{1c} outcomes is available at: https://pm-cardoso.shinyapps.io/SGLT2_GLP1_calculator/.

Discussion

We have developed and validated a novel treatment selection algorithm using state-of-the-art Bayesian methods to predict differences in one-year glycaemic outcomes for SGLT2i and GLP1-RA therapies. Our evaluation shows that glycaemic response-based targeting of these two major drug classes to individuals with type 2 diabetes based on their characteristics can not only optimise glycaemic control, but may also associate with improved tolerability and reduced risk of new-onset microvascular complications. In contrast, we found limited evidence for heterogeneity in other clinical outcomes, with overall equipoise between the two therapies for new-onset MACE and a clear overall benefit with SGLT2i over GLP1-RA for new-onset heart failure and adverse kidney outcomes independent of differences in glycaemic efficacy (differences which themselves reflect differences in the clinical characteristics of individual patients). Predictions are based on routine clinical characteristics, meaning the model could be deployed in many countries worldwide where these agents are available, without the need for additional testing.

Our approach differs from notable recent studies that have attempted to subclassify people with type 2 diabetes or used dimensionality reduction to represent type 2 diabetes heterogeneity [6, 27, 28]. Whilst these approaches can provide important insight into underlying heterogeneity of

type 2 diabetes, they, by definition, lose information about the specific characteristics of individual patients, meaning they could be suboptimal for accurately predicting the treatment or disease progression outcomes for individuals [29]. If subclassification approaches based on clinical features are to have potential clinical utility, they will need to be updated over time as an individual's phenotype evolves [30]. In contrast, our 'outcomes-based' approach enables the prediction of optimal therapy when a treatment decision is made, uses the specific information available for a patient at that point in time and avoids subclassification.

Although BCF models are only causal under specific assumptions [31], our study might provide insights into differences in the possible underlying mechanisms of action of GLP1-RA and SGLT2i, and the clinical utility of these differences. The strongest predictor of a differential glycaemic response was the number of currently prescribed glucose-lowering therapies, which is a likely proxy of the degree of diabetes progression (and, therefore, underlying beta cell failure) of an individual. A plausible biological explanation for this proxy is an attenuated GLP1-RA response in individuals with markers of beta cell failure including longer diabetes duration and lower fasting C-peptide, as previously demonstrated in a prospective population-based analysis [7], with no evidence of differences for SGLT2i [31]. Whilst in contrast, post hoc analyses of clinical trials have found type 2 diabetes duration and beta cell function do not modify glycaemic outcomes with GLP1-RA [19, 32, 33], this may reflect trial inclusion criteria as participants had relatively higher beta cell function compared with population-based cohorts [34]. The favouring of GLP1-RA over SGLT2i in women is novel but is supported by our trial validation and recent pharmacokinetic data demonstrating higher circulating GLP1-RA drug concentrations and, consequently, greater HbA_{1c} reduction in female compared with male participants [33]. For SGLT2i, increased urinary glucose excretion likely explains the greater relative glycaemic efficacy with higher baseline HbA_{1c} and eGFR, which, in concordance with our analysis, has been previously demonstrated in trial data [35]. Given the lack of previous studies evaluating whether the relative glucose-lowering efficacy of the two drug classes is altered by baseline HbA_{1c} [6], an interesting finding is that our model suggests a greater relative glycaemic benefit with SGLT2i over GLP1-RA at higher baseline HbA_{1c} levels, which warrants further study. Of note, the comorbidities included in the final model had modest effects on HbA_{1c} and are likely to be proxy measures of factors underlying differential response to these therapies.

A further interesting finding is that mean HbA_{1c} response on both drug classes was similar, and weight loss slightly greater with SGLT2i, in contrast to RCTs where network meta-analysis suggests a greater glycaemic and weight

efficacy of most individual GLP1-RA over SGLT2i [12, 36, 37]. The relative average equipoise between the two drug classes in our study is likely indicative of a diminished real-world response to GLP1-RA, a phenomenon also documented in other real-world studies [37, 38], which may relate to reduced real-world adherence to GLP1-RA [38].

Our study represents the second application of our novel validation framework for precision medicine models, which, in the absence of true observed outcomes (for an individual patient on one therapy, the counterfactual outcome they would have had on an alternative therapy cannot be observed [39]), evaluates accuracy in subgroups defined by predicted CATE. The previous study developed a treatment selection model for SGLT2i vs DPP4i therapy in an independent dataset. Although this previous model demonstrated marked heterogeneity in the relative glycaemic outcome, most (84%) individuals had a greater glycaemic reduction with SGLT2i. In contrast, this GLP1-RA/SGLT2i model shows greater heterogeneity in treatment effects but with equipoise on ATE between the two therapies (52% favouring GLP1-RA). Furthermore, we demonstrate that optimising therapy based on predicted glycaemic response may lower microvascular complication risk, a finding concordant with evidence from the UKPDS study on the importance of good glycaemic control to lower the risk of microvascular disease [23, 40].

Further developments to this model could include the incorporation of non-routine and pharmacogenetic markers (recently identified for GLP1-RA) [41], and additional glucose-lowering drug classes, in particular, off-patent sulfonylureas and pioglitazone, to support the deployment of the algorithm in lower-income countries where the availability of newer medications may be limited. Assessment of semaglutide, a GLP1-RA with potent glycaemic effect excluded here due to low numbers prescribed during the period of data availability, and tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist not currently available in the UK, is an important area for future research as our model may benefit from recalibration for these newer therapies. Although our ethnicity-specific validation suggests good performance in individuals of South Asian, Black, Other and Mixed ethnicity, setting and ethnicity-specific validation and optimisation would also improve future clinical utility. Given the possibility of selection bias due to non-random treatment assignment, validation in a dataset where individuals were randomised to therapy would further strengthen the evidence for model deployment. However, few active comparator trials of these two drug classes have been conducted [8] and, to our knowledge, none are available for data sharing. Ultimately, research, likely in even larger datasets, is needed on whether individualised models for other short- and long-term outcomes beyond glycaemia, particularly cardiorenal disease, can further improve current prescribing approaches [42]. Finally, a limitation of our study is that despite being state-of-the-art and with a key advantage of allowing estimation of

predictions with uncertainty, and so facilitating more transparent evaluation, the BCF methods we applied are subject to ongoing development in several key areas such as variable selection [18, 19], scalability and handling of missing data [20].

In conclusion, our study demonstrates a clear potential for targeted prescribing of GLP1-RA and SGLT2i to individual people with type 2 diabetes based on their clinical characteristics to improve glycaemic outcomes, tolerability and risk of microvascular complications. This provides an important advance on current type 2 diabetes guidelines, which only recommend preferentially prescribing these therapies to individuals with, or at high risk of, cardiorenal disease, with no clear evidence to choose between the two drug classes. Precision type 2 diabetes prescribing based on routinely available characteristics has the potential to lead to more informed and evidence-based decisions on treatment for people with type 2 diabetes worldwide in the near future.

Supplementary Information The online version contains peer-reviewed but unedited supplementary material available at <https://doi.org/10.1007/s00125-024-06099-3>.

Acknowledgements This article is based in part on data from the CPRD obtained under license from the UK Medicines and Healthcare products Regulatory Agency. CPRD data are provided by patients and collected by the UK National Health Service (NHS) as part of their care and support. Approval for CPRD data access and the study protocol was granted by the CPRD Independent Scientific Advisory Committee (eRAP protocol number: 22_002000). This publication is based in part on research using data from GSK that has been made available through secured access. GSK has not contributed to or approved, and is not in any way responsible for, the contents of this publication. The PRIBA study was funded by a National Institute for Health Research (UK) Doctoral Research Fellowship (DRF-2010-03-72, AGJ) and supported by the National Institute for Health Research (NIHR) Clinical Research Network. The authors thank the members of the Predicting Response to Incretin Based Agents (PRIBA) study group and all cohort participants (see ESM for a list of PRIBA study group members). ATH and BMS are supported by the NIHR Exeter Clinical Research Facility; the views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. PC, KGY, JB, TJM and JMD are supported by Research England's Expanding Excellence in England (E3) fund. The authors acknowledge contributions from the wider MASTERMIND consortium who supported this work (see ESM for a list of MASTERMIND consortium members). The authors acknowledge support from the National Institute for Health and Care Research Exeter Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Data availability The UK routine clinical data analysed during the current study are available in the CPRD repository (CPRD; <https://cprd.com/research-applications>), but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. For re-using these data, an application must be made directly to CPRD. Data from Scotland are anonymised real-world medical records available by request through the Scottish Care Information-Diabetes Collaboration, Tayside & Fife, Scotland unit (<https://www.sci-diabetes.scot.nhs.uk/>). Clinical trial data are not publicly available; for access an application must be made directly to GSK and www.ClinicalStudyDataRequest.com.

Code availability All R code used for the analysis is provided at <https://github.com/Exeter-Diabetes/CPRD-Pedro-SGLT2vsGLP1>.

Funding This research was funded by the Medical Research Council (UK) (MR/N00633X/1) and a BHF-Turing Cardiovascular Data Science Award (SP/19/6/34809).

Authors' relationships and activities APM declares previous research funding from Eli Lilly and Company, Pfizer and AstraZeneca. BAM holds an honorary post at University College London for the purposes of carrying out independent research, and declares payments to their institution from the Medical Research Council (MRC), Health Data Research UK (HDRUK) and British Heart Foundation (BHF). NS declares personal fees from Abbott Diagnostics, Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer and Sanofi and grants to his University from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics. RRH reports research support from AstraZeneca, Bayer and Merck Sharp & Dohme, and personal fees from Anji Pharmaceuticals, Bayer, Novartis and Novo Nordisk. JB is an employee of Novo Nordisk, outside of the submitted work. ERP has received honoraria for speaking from Lilly, Novo Nordisk and Illumina. AGJ has received research funding from the Novo Nordisk foundation. Representatives from GSK, Takeda, Janssen, Quintiles, AstraZeneca and Sanofi attend meetings as part of the industry group involved with the MASTERMIND consortium. No industry representatives were involved in the writing of the manuscript or analysis of data. For all authors these are outside the submitted work. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work

Contribution statement PC, JMD, BMS, TJM, ATH, AGJ and ERP conceived and designed the study. PC, with support from JMD, BMS and TJM analysed the data and developed the code. KGY, RH and APM helped with curating the CPRD dataset. ATNN, PK, EH and LD helped analyse the Scottish independent dataset. All authors contributed to the writing of the article, provided support for the analysis and interpretation of results, critically revised the article and approved the final article. TJM and JMD are the guarantors of this work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.





References

- Dennis JM (2020) Precision medicine in type 2 diabetes: using individualized prediction models to optimize selection of treatment. *Diabetes* 69(10):2075–2085. <https://doi.org/10.2337/dbi20-0002>
- Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 65(12):1925–1966
- Cefalu WT, Kaul S, Gerstein HC et al (2018) Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors' expert forum. *Diabetes Care* 41(1):14–31. <https://doi.org/10.2337/dci17-0057>
- McGovern A, Feher M, Munro N, de Lusignan S (2017) Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use. *Diabetes Ther* 8:365–376. <https://doi.org/10.1007/s13300-017-0254-7>
- Shields BM, Dennis JM, Angwin CD et al (2023) Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. *Nat Med* 29:376–383. <https://doi.org/10.1038/s41591-022-02120-7>
- Dennis JM, Young KG, McGovern AP et al (2022) Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. *Lancet Digital Health* 4(12):873–883. [https://doi.org/10.1016/S2589-7500\(22\)00174-1](https://doi.org/10.1016/S2589-7500(22)00174-1)
- Jones AG, McDonald TJ, Shields BM et al (2016) Markers of β -cell failure predict poor glycaemic response to GLP-1 receptor agonist therapy in type 2 diabetes. *Diabetes Care* 39(20):250–257. <https://doi.org/10.2337/dc15-0258>
- Dawed AY, Mari A, Brown A et al (2023) Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. *Lancet Diabetes Endocrinol* 11(1):33–41. [https://doi.org/10.1016/S2213-8587\(22\)00340-0](https://doi.org/10.1016/S2213-8587(22)00340-0)
- Wolf A, Dedman D, Campbell J et al (2019) Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. *Int J Epidemiol* 48(6):1740–1740g. <https://doi.org/10.1093/ije/dyz034>
- Rodgers LR, Weedon MN, Henley WE, Hattersley AT, Shields BM (2017) Cohort profile for the MASTERMIND study: using the clinical practice research datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes. *BMJ Open* 7:e017989. <https://doi.org/10.1136/bmjopen-2017-017989>
- National Institute for Health and Care Excellence (2015) Type 2 diabetes in adults: management. Available from: <https://www.nice.org.uk/guidance/ng28>. Accessed 5 Apr 2023
- Tsapas A, Avgerinos I, Karagiannis T et al (2020) Comparative effectiveness of glucose-lowering drugs for type 2 diabetes. *Ann Int Med* 173(4):278–286. <https://doi.org/10.7326/M20-0864>
- Pratley RE, Nauck MA, Barnett AH et al (2014) Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. *Lancet Diabetes Endocrinol* 2(4):289–297. [https://doi.org/10.1016/S2213-8587\(13\)70214-6](https://doi.org/10.1016/S2213-8587(13)70214-6)
- Grams ME, Brunskill NJ, Ballew SH et al (2022) Development and validation of prediction models of adverse kidney outcomes in the population with and without diabetes. *Diabetes Care* 45(9):2055–2063. <https://doi.org/10.2337/dc22-0698>
- Inker LA, Eneanya ND, Coresh J et al (2021) New creatinine- and cystatin c-based equations to estimate GFR without race. *N Engl J Med* 385(19):1737–1749. <https://doi.org/10.1056/NEJMoa2102953>
- Hahn PR, Murray JS, Carvalho CM (2020) Bayesian regression tree models for causal inference: regularization, confounding, and heterogeneous effects (with discussion). *Bayesian Anal* 15(3):965–1056. <https://doi.org/10.1214/19-BA1195>
- Caron A, Baio G, Manopoulou I (2021) Shrinkage Bayesian causal forests for heterogeneous treatment effects estimation. *J Comput Graph Stat* 31(4):1202–1214. <https://doi.org/10.1080/10618600.2022.2067549>
- Hill JL (2011) Bayesian nonparametric modelling for causal inference. *Bayesian Nonparametric* 20(1):217–240. <https://doi.org/10.1198/jcgs.2010.08162>
- Caron A (2020) SparseBCF: sparse Bayesian causal forest for heterogeneous treatment. R package version 1.0
- Kapelner A, Bleich J (2016) bartMachine: machine learning with Bayesian additive regression trees. *J Stat Softw* 70(4):1–40
- Cardoso P, Dennis JM, Bowden J, Shields BM, McKinley TJ (2024) Dirichlet process mixture models to impute missing predictor data in counterfactual prediction models: an application to

- predict optimal type 2 diabetes therapy. *BMC Med Inform Decis Mak* 24(1):12. <https://doi.org/10.1186/s12911-023-02400-3>
22. Holland PW (1985) Statistics and causal inference. *J Am Stat Assoc* 81(396):945–960. <https://doi.org/10.1080/01621459.1986.10478354>
 23. Harrell FE (2016) Regression modeling strategies. Springer International Publishing
 24. Hippisley-Cox J, Coupland C, Vinogradova Y et al (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ* 336(7659):1475–1482. <https://doi.org/10.1136/bmj.39609.449676.25>
 25. Collins GS, Reitsma JB, Altman DG, Moons KG (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *Ann Int Med* 162(1):55–63. <https://doi.org/10.7326/M14-0697>
 26. Ahlqvist E, Storm P, Käräjämäki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol* 6(5):361–369. [https://doi.org/10.1016/S2213-8587\(18\)30051-2](https://doi.org/10.1016/S2213-8587(18)30051-2)
 27. Nair ATN, Wesolowska-Andersen A, Brorsson C et al (2022) Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. *Nat Med* 28:982–988. <https://doi.org/10.1038/s41591-022-01790-7>
 28. Udler MS, Kim J, von Grotthuss M et al (2018) Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. *PLOS Med* 15(9):e1002654. <https://doi.org/10.1371/journal.pmed.1002654>
 29. Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019) Clusters provide a better holistic view of type 2 diabetes than simple clinical features - author's reply. *Lancet Diabetes Endocrinol* 7(9):669. [https://doi.org/10.1016/S2213-8587\(19\)30250-5](https://doi.org/10.1016/S2213-8587(19)30250-5)
 30. Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. *Lancet Diabetes Endocrinol* 7(9):684–694. [https://doi.org/10.1016/S2213-8587\(19\)30187-1](https://doi.org/10.1016/S2213-8587(19)30187-1)
 31. Gallwitz B, Dagogo-Jack S, Thieu V et al (2018) Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. *Diabetes Obes Metab* 20(2):409–418. <https://doi.org/10.1111/dom.13086>
 32. Mathieu C, Prato S, Botros F et al (2018) Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme. *Diabetes Obes Metab* 20(8):2023–2028. <https://doi.org/10.1111/dom.13313>
 33. Bonadonna R, Blonde L, Antsiferov M et al (2017) Lixisenatide as add-on treatment among patients with different β -cell function levels as assessed by HOMA- β index. *Diabetes Metab Res Rev* 33(6):e2897. <https://doi.org/10.1002/dmrr.2897>
 34. Overgaard RV, Hertz CL, Ingwersen SH, Navarria A, Drucker DJ (2021) Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. *Cell Rep Med* 2(9):100387. <https://doi.org/10.1016/j.xcrm.2021.100387>
 35. Young KG, McInnes EH, Massey RJ et al (2023) Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review. *Commun Med* 3(1):131. <https://doi.org/10.1038/s43856-023-00359-w>
 36. Edelman S, Polonsky W (2017) Type 2 diabetes in the real world: the elusive nature of glycemic control. *Diabetes Care* 40(11):1425–1432. <https://doi.org/10.2337/dc16-1974>
 37. Weiss T, Yang L, Carr R et al (2022) Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. *BMJ Open Diabetes Res Care* 10(1):e002517. <https://doi.org/10.1136/bmjdr-2021-002517>
 38. Carls G, Tuttle E, Tan R-D et al (2017) Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. *Diabetes Care* 40(11):1469–1478. <https://doi.org/10.2337/dc16-2725>
 39. Stratton IM, Adler AI, Neil HAW et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *Br Med J* 321(7258):405–412. <https://doi.org/10.1136/bmj.321.7258.405>
 40. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 359(15):1577–1589. <https://doi.org/10.1056/NEJMoa0806470>
 41. Patoulias DI, Katsimardou A, Kalogirou MS et al (2020) Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints. *Diabetes Metab* 46(4):272–279. <https://doi.org/10.1016/j.diabet.2020.04.001>
 42. McMurray JJ, Sattar N (2022) Heart failure: now centre-stage in diabetes. *Lancet Diabetes Endocrinol* 10(10):689–691. [https://doi.org/10.1016/S2213-8587\(22\)00249-2](https://doi.org/10.1016/S2213-8587(22)00249-2)

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Pedro Cardoso¹  · Katie G. Young¹  · Anand T. N. Nair² · Rhian Hopkins¹  · Andrew P. McGovern¹ · Eram Haider² · Piyumanga Karunaratne² · Louise Donnelly² · Bilal A. Mateen³ · Naveed Sattar⁴ · Rury R. Holman^{5,6} · Jack Bowden¹ · Andrew T. Hattersley¹ · Ewan R. Pearson² · Angus G. Jones¹ · Beverley M. Shields¹ · Trevelyan J. McKinley¹ · John M. Dennis¹  on behalf of the MASTERMIND consortium

✉ John M. Dennis
j.dennis@exeter.ac.uk

¹ Institute of Biomedical & Clinical Science, University of Exeter Medical School, Exeter, UK

² Division of Molecular & Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

³ Institute of Health Informatics, University College London, London, UK

⁴ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

⁵ Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK

⁶ Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK